Evidence map›Paper›PMID 33668317›Full record

ArticlePharmaceutics2021

Understanding Carrier Performance in Low-Dose Dry Powder Inhalation: An In Vitro

Joana T Pinto, Inês Cachola, João F Pinto, Amrit Paudel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.Journal of aerosol medicine and pulmonary drug delivery · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Joana T PintoResearch Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria.
Inês CacholaResearch Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria.
João F PintoiMed.ULisboa-Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
Amrit PaudelResearch Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria.

Funding

Österreichische Forschungsförderungsgesellschaft COMET
6 · The paper itself

Abstract

The use of physiologically based pharmacokinetic (PBPK) models to support drug product development has become increasingly popular. The in vitro characterization of the materials of the formulation provides valuable descriptors for the in silico prediction of the drug's pharmacokinetic profile. Thus, the application of an in vitro

Indexed as

carrier propertiesdry powder inhalation (DPI)lactosephysiologically based pharmacokinetic (PBPK) modelpowder flowsalbutamol sulphate

Identifiers

PMID33668317
PMCPMC8025906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.